Form 4: Inozyme Pharma SVP, CFO Sanjay Subramanian Reports Acquisition of Stock Options and Restricted Stock Units

Sanjay Subramanian, SVP and CFO of Inozyme Pharma, reports the acquisition of stock options and restricted stock units on March 11, 2025.

Summary

• On March 11, 2025, Sanjay Subramanian, the SVP and CFO of Inozyme Pharma, acquired stock options and restricted stock units.
• The stock options grant was for 145,000 shares with an exercise price of $1.06 per share.
• These options vest in equal monthly installments over four years from the grant date.
• Additionally, 38,500 restricted stock units (RSUs) were granted, each representing a contingent right to receive one share of common stock.
• 33% of the RSUs vest on March 11, 2026, with the remaining 67% vesting in equal quarterly installments until March 11, 2028.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally viewed neutrally to positively as it incentivizes management. The sentiment is moderately positive as it indicates the company is investing in its leadership.

Positives

• The grant of stock options and RSUs aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

This type of equity compensation is standard practice in the pharmaceutical industry to incentivize key executives and align their interests with the long-term success of the company. Companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals also use similar compensation packages.

Comparison to Industry Standards

• Equity grants are a common component of executive compensation packages in the biotech industry.
• Companies like BioMarin and Vertex typically grant stock options and RSUs with similar vesting schedules to their executives.
• The size of the grant is relative to the executive's role and the company's overall compensation strategy.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with the company's performance.
• Employees may see this as a positive sign of investment in leadership.

Key Dates